ASH 2025 Oral Presentation: Innovent Biologics Announces Initial Results of the First-in-Human Phase 1 Study of Trispecific Antibody IBI3003 in Relapsed or Refractory Multiple Myeloma
SAN FRANCISCO and SUZHOU, China, Dec. 8, 2025 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures, and commercializes high-quality medicines for the treatment of...
Strava Releases 12th Annual Year in Sport Trend Report, Revealing That Doomscrolling Is Out, Movement Is In
New global data shows how Gen Z is prioritising fitness, connection, and community—plus unveils the year's top gear and new global city leaderboards. SAN FRANCISCO, Dec. 3, 2025 /PRNewswire/ -- Strava, the app for active people with over 180 million...
Visa Data Shows Affluent Leading Post-Race Tourism and Spending after the Singapore Grand Prix
One in five[1] travellers visiting Singapore continued their journey after the Grand Prix to top destinations including Indonesia, Malaysia, Thailand, Australia and Japan SINGAPORE, Oct. 31, 2025 /PRNewswire/ -- Visa, the world leader in digital...
Kelun-Biotech Presents Positive Results of Phase 3 Clinical Study OptiTROP-Breast02 for Sacituzumab Tirumotecan in Advanced HR+/HER2- Breast Cancer at 2025 ESMO
CHENGDU, China, Oct. 18, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") announced that at the 2025 European Society for Medical Oncology (ESMO) Congress held in Berlin, Germany, results from a Phase 3...
e-STORAGE's SolBank 3.0 Successfully Passes Large-Scale Fire Testing (LSFT)
KITCHENER, ON, June 3, 2025 /PRNewswire/ -- Canadian Solar Inc. (the "Company" or "Canadian Solar") (NASDAQ: CSIQ) today announced that e-STORAGE, which is part of the Company's majority-owned subsidiary CSI Solar Co., Ltd. ("CSI Solar"), has...
Science and Technology Daily: Into Tech Park: Zooming In on China's Innovative Spirit
TIANJIN, China, May 20, 2025 /PRNewswire/ -- Imagine controlling objects with your mind, like a Marvel Comic superhero. In Tianjin, this fantasy is becoming reality. Picture Osuagwu Obinna Ikechukwu, a young Nigerian researcher at the University of...
Dizal's Golidocitinib in Combination with Anti-PD-1 Shows Promise in IO Resistant Non-Small Cell Lung Cancer
Golidocitinib is a JAK1 only inhibitor approved for the treatment of relapsed or refractory PTCL The combination of golidocitinib and PD-1 antibody showed synergistic anti-tumor effects in anti-PD-1-resistant NSCLC SHANGHAI, March 20, 2025...
Agoda Survey Reveals: Strong Interest in Family Travel and New Destinations Among South Korean Women
SEOUL, South Korea, March 11, 2025 /PRNewswire/ -- To mark International Women's Day which took place on March 8, digital travel platform Agoda unveiled travel insights about South Korean women. The findings revealed that while both men and women...
Global Times: Up Close: President Xi joins national political advisors in education discussion
BEIJING, March 9, 2025 /PRNewswire/ -- Chinese President Xi Jinping, also general secretary of the Communist Party of China (CPC) Central Committee and chairman of the Central Military Commission, visited national political advisors from the China...
SECuRE trial update: 92% of pre-chemo participants experience greater than 35% drop in PSA levels across all cohorts. Cohort Expansion Phase commences.
HIGHLIGHTS Safety Review Committee (SRC) meeting confirms end of the Dose Escalation Phase and commencement of the Cohort Expansion Phase (Phase II stage) of the SECuRE study. Based on the efficacy and safety assessment of all cohorts and the focus...